Replies to post #53063 on US Stem Cell Inc (USRM)

[Havoc23]

Additionally, the FDA needs to see that usrm has the financial means to accommodate an RMAT designation and reactivated phase 2/3 trial.

In steps GACP with $5 million on hand.

Ball is now in the fda's court